By leveraging our experience in biopharmaceuticals and small molecule drug process development and scale-up, Lonza can now manufacture a new class of high potency biologicals to support both clinical development and commercial licensing of Antibody Drug Conjugates (ADCs).
There are many unique challenges in manufacturing highly potent biopharmaceuticals that have encouraged Lonza to design and build a new large-scale manufacturing plant dedicated solely to highly potent production in Visp, Switzerland. As pioneers in developing innovative manufacturing pathways for Active Pharmaceutical Ingredients (APIs), Lonza ADC experts offer superior services in the production of your next generation of pharmaceuticals.
Lonza offers a variety of production capacities including small scale and large scale production for your complete pipeline needs.
Our Capabilities and Services for ADC Production Include:
- Multipurpose cGMP Plants Dedicated for ADC Products
- Qualified Equipment
- Biopharmaceutical Environmental
- Small Scale Capacities of 2x10L, 3x20L, 2x35L, 3 UF Skids
- Large Scale Capacities of 1x100L, 1x200L, 2x300L, 2x600L, 2 UF Skids
To learn more about our ADC manufacturing facilities visit our Visp, Switzerland site page.